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Abstract
Elevated levels of FGF23 in individuals with chronic kidney disease (CKD) are associated
with adverse health outcomes, such as increased mortality, large vessel disease, and
reduced white matter volume, cardiovascular and cerebrovascular events. Apart from the
well-known link between cardiovascular (CV) risk factors, especially diabetes and hyperten-
sion, and cerebrovascular damage, elevated FGF23 is also postulated to be associated with
cerebrovascular damage independently of CKD. Elevated FGF23 predisposes to vascular
calcification and is associated with vascular stiffness and endothelial dysfunction in the gen-
eral population with normal renal function. These factors may lead to microangiopathic
changes in the brain, cumulative ischemia, and eventually to the loss of white matter fibers.
The relationship between FGF23 and brain integrity in individuals without CKD has hitherto
not been investigated. In this study, we aimed to determine the association between
FGF23, and white matter integrity in a cohort of 50 participants with varying degrees of CV
risk burden, using high resolution structural human brain connectomes constructed from
MRI diffusion images. We observed that increased FGF23 was associated with axonal loss
in the frontal lobe, leading to a fragmentation of white matter network organization. This
study provides the first description of the relationship between elevated levels of FGF23,
white matter integrity, and brain health. We suggest a synergistic interaction of CV risk fac-
tors and FGF23 as a potentially novel determinant of brain health.
Introduction
Fibroblast growth factor-23 (FGF23) is an osteocyte derived phosphaturic hormone that regu-
lates calcium-phosphate and vitamin D metabolism by activating the FGF receptor-α-klotho
complex in the kidney[1]. FGF23 induces phosphaturia by decreasing renal reabsorption of
phosphate in the proximal tubule, and inhibiting calcitriol (hormonally active metabolite of
vitamin D) synthesis[1, 2]. Calcitriol functions to increase calcium and phosphate levels in the
blood by increasing kidney and gastrointestinal absorption, and increasing calcium and
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phosphate release from bone into the blood through bone resorption. Calcitriol inhibition by
FGF23 induces calcium deficiency resulting in even more production of calcium from the
bone. Excess circulating calcium eventually leads to arterial and vascular calcification[3].
Chronic Kidney Disease (CKD) is possibly the most common cause of elevated FGF23, which
has been implicated in increased cardiovascular mortality of CKD patients. Elevated FGF23 is
also associated with cardiovascular disease, left ventricular hypertrophy [4, 5], and is a putative
indicator of Cardiovascular (CV) risk factors [6]. Apart from CKD, high phosphorous diet
stimulates FGF23 production, leading to elevated levels of FGF23 [7]. Even among individuals
without CKD, elevated levels of FGF23 have been postulated to increase the risk of stroke [8].
Nonetheless, the effects of elevated FGF23 on brain health in non-stroke individuals have not
fully been determined. Compared with brain gray matter, white matter is significantly more
susceptible to small vessel ischemic injury because it receives less perfusion when adjusting for
metabolic demands, due to lower collateral blood supply to deep white matter [9]. Moreover,
the maintenance of structural integrity of medium to long range axonal projections is metabol-
ically demanding. For these reasons, we postulated that FGF23 would lead to white matter
compromise particularly within the brain areas with long cortico-cortical, or cortico-subcorti-
cal axonal projections, such as the frontal lobes.
We therefore aimed to identify the effects of FGF23 independent of kidney disease by
studying a prospective cohort with normal kidney function, but with CV risk factors that
included diabetes, hypertension, and hyperlipidemia. We employed the novel neuroimaging
method of the high-resolution human brain connectome to fully map white matter networks
across the entire brain. We aimed to determine the relationship between FGF23 and neuronal
network integrity, with the goal of elucidating the mechanistic aspects related to the impact of
FGF23 on brain health. We postulated a synergistic interaction of CV risk factors and FGF23
as a determinant of brain health.
Methods
Participants
We recruited 51 older participants, (40 females, mean age 55.3 ± 8.6 years) without a history of
neurological or psychiatric diseases from the local community through advertisement. All par-
ticipants were self-reported cognitively normal adults. There were 23 African American and 28
white participants. Twenty-eight participants did not have a history of cardiovascular risk fac-
tors, while 23 participants had previously been diagnosed with at least one CV risk factor (CV
group): diabetes (11 participants), hyperlipidemia (15 participants), and hypertension (16 par-
ticipants). Six participants had been diagnosed with all CV risk factors. These diagnoses were
obtained through medical chart review. The Charlson Comorbidity Index[10] (CCI) was calcu-
lated for all participants, including a diagnosis of hypertension and hyperlipidemia at a score of
one each to the overall score. BMI and smoking history were not available for all participants
and therefore not included in the analyses. Participants were stratified into two groups: CV risk
factor and normal controls based on a previous diagnosis of a cardiovascular disease. One par-
ticipant had chronic kidney disease and was therefore excluded from further analysis. All partic-
ipants included in the analysis had normal renal function. The study was approved by the
Institutional Review Boards at the Medical University of South Carolina. Written informed con-
sent was obtained from all participants, as approved by our institutions’ IRB.
FGF23 acquisition
Circulating FGF23 was measured using the Human FGF23 ELISA kit from Millipore
(EZHFGF23-32K). Samples were collected in EDTA containing tubes and centrifuged at 2-3K
FGF23 and the brain
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to obtain the plasma. Samples were prepared as described by the manufacturer and the con-
centrations of FGF23 were determined from the standards provided. FGF23 is presented as
pg/ml of plasma.
Image acquisition
Imaging was performed on a Siemens 3T TIM trio MRI scanner located at the Medical Univer-
sity of South Carolina. We used volumetric T1-weighted and Diffusion images collected from
each participant. T1 parameters: MPRAGE sequence with 1 mm isotropic voxels, 256x256
matrix size, and a 9-degree flip angle. We used a 192-slice sequence with TR = 2250 ms,
T1 = 925 ms, and TE = 4.11 ms. DTI parameters: twice-refocused echo-planar imaging b = 0,
1000, 30 diffusion encoding directions, TR = 8500 ms, TE = 98 ms, FOV = 222 x 222 mm2,
matrix = 74 x 74, 3 mm slice thickness, and 40 axial slices.
Structural connectome construction
Each participant’s individual high-resolution structural connectome was built from structural
T1 and diffusion tensor imaging (DTI) neuroimaging data using the following steps: 1.T1
weighted images were spatially registered into standard space and segmented into probabilistic
grey and white matter maps using SPM12’s unified segmentation-normalization; 2.Each indi-
vidual’s grey matter map was divided into 1358 approximately evenly sized regions using the
Atlas of Intrinsic Connectivity of Homotopic Areas (AICHA) brain atlas [11]; 3.The grey mat-
ter parcellation maps were then non-linearly registered into the diffusion imaging (DTI)
space, and pairwise probabilistic DTI fiber tracking was computed for all possible pairs of grey
matter regions 4. The weight of each pairwise connectivity link was determined based on the
number of probabilistic streamlines connecting the grey matter region pair, corrected by dis-
tance travelled by each streamline and by the total volume of the connected regions. Finally,
a weighted adjacency matrix M of size 1358 x 1358 was constructed for each participant with
Mi,j representing the weighted link between region of interest (ROI) i and ROI j. Tractography
was estimated through the software FSL FMRIB’s Diffusion Toolbox (FDT), including eddy
current correction, motion correction[12], and probabilistic method [13] with BEDPOST
being used to assess default distributions of diffusion parameters at each voxel, and probabilis-
tic tractography was performed using FDT’s probtrackX (parameters: 5000 individual path-
ways drawn through the probability distributions on principal fiber direction, curvature
threshold set at 0.2, 200 maximum steps, step length 0.5mm, and distance correction). The
weighted connectivity between the regions i and j was defined as the number of probabilistic
streamlines arriving at j region when i was seeded, averaged with the number of probabilistic
streamlines arriving at i region when j was seeded.
Fig 1 provides a workflow of the connectome construction process and network analysis.
Modular organization detection
The integrity of neuronal network architecture can be assessed through the quantification of
the modular parcellation of the network (modularity). Modularity provides a measurement of
the balance between segregation and integration of the network in its entirety, or within
regional sub-networks. This balance is known to be a fundamental principle in biological net-
work organization, including neuronal networks [14]. Our analysis was based on the modular
organization of each brain region for every participant. For each participant the whole brain
connectome was divided into the left and right frontal, temporal, parietal, and occipital lobe
sub-networks. The lobe sub-networks were assessed regarding their modularity using New-
man’s modularity algorithm [15] implemented in the Brain Connectivity Toolbox [16], (e.g.
FGF23 and the brain
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[Ci,Q] = modularity_und(W), where W is the weighted undirected connectivity matrix;
gamma was maintained at the default: gamma = 1).
Statistical analyses
For each group (CV risk factor and healthy controls), we performed general linear regression
analysis to examine the relationship between brain integrity and FGF23, adjusting for key
covariates–sex, race, and CCI. Linear regressions were modelled for each group separately to
minimize noise inherent in the healthy control group, and to avoid type II error. Brain integ-
rity measured via modularity was set as the dependent variable, and FGF23, sex, race and CCI
as the predictor variables. We used this model to determine the association between FGF23,
and the integrity of each brain region (modularity scores for the frontal, temporal, parietal and
occipital regions) for both left and right hemispheres. Linear correlations were evaluated using
a two-tailed Pearson correlation coefficient. We evaluated the association between FGF23 and
modularity of the left and right frontal hemispheres. Correlation was performed independently
on the CV risk factor group and the control group.
We further assessed the overall connectivity of the frontal lobe by calculating the density; a
measure of axonal integrity; as the number of all connections present. We then determined the
relationship between FGF23 and fiber density of the left and right hemisphere frontal regions.
Of the 22 participants with CV risk factors, 17 had serum creatinine scores from the latest
available comprehensive metabolic panel obtained from the hospital. We re-calculated the
Pearson correlation for these participants, with partial correlations accounting for the creati-
nine score. Natural log transformed FGF23 scores were used in all analyses. All statistical anal-
yses were performed using MATLAB. The statistical significance was set at p 0.05.
Results
To account for possible confounding by age, sex and race, we determined the association
between these factors and FGF23. Pearson analysis revealed no correlation between age and
FGF23 (r = 0.13, p = 0.17), and student’s t-test revealed no differences in FGF23 levels between
female and male participants two-sample t(48) = 0.91, p = 0.37, or between African American
and Caucasian participants two-sample t(48) = 0.53, p = 0.6. There was also no significant dif-
ference in FGF23 levels between the control and CV risk factor groups, two-sample t(48) =
0.69, p = 0.49.
Relationship between modularity and FGF23
Our model revealed that FGF23 was associated with left hemisphere frontal lobe modularity in
the CV risk factor group: F(4,22) = 4.2, p = 0.015, adjusted R2 = 0.38 (Table 1). FGF23 was not
associated with brain integrity among individuals without CV risk factors. In that group, brain
integrity was associated with sex, race and CCI (Table 2). A model of only FGF23 (predictor
variable) and left hemisphere frontal lobe modularity (dependent variable) revealed that
FGF23 levels alone accounted for about 29% of brain integrity in the left hemisphere frontal
lobe of participants with CV risk factors: F(1,22) = 9.46, p = 0.006, adjusted R2 = 0.29, while
the same was not observed in the control group: F(1,22) = 0.6, p = 0.45, adjusted R2 = 0.015.
Fig 1. Connectome generation and network analysis. In A, the T1 image is normalized, and segmented (into CSF, gray and white matter). The gray
matter is parcellated into 1358 regions of interest (ROI). The T1 is warped into diffusion space where fiber tracking occurs, finding the connections
between each pair of ROIs, generating a connectome, or network of connectivity between all brain regions. C is an example of whole brain modular
partition into modules using Newman’s modularity algorithm, which groups ROIs that are more closely associated by their white matter networks and
relatively segregated from surrounding groups (each module is represented by the same color).
https://doi.org/10.1371/journal.pone.0203460.g001
FGF23 and the brain
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Linear correlations revealed that left hemisphere frontal lobe modularity was significantly
correlated with FGF23 (Fig 2A left panel) in participants with CV risk factors, such that higher
modularity was associated with higher FGF23 levels (r = 0.57, p = 0.006). This association was
also significant when controlling for creatinine levels (n = 17) (partial correlation controlling
for creatinine: r = 0.48, p = 0.03). In the control group, the left hemisphere frontal lobe modu-
larity was not associated with FGF23 levels (Fig 2A right panel, r = 0.05, p = 0.4).
The right hemisphere frontal lobe was not associated with FGF23 in the CV risk factor
group (r = 0.22, p = 0.33) or control group (r = 0.12, p = 0.55). Correcting for multiple compar-
isons (0.05/8), the left hemisphere frontal lobe modularity was still significantly correlated
with FGF23.
Relationship between density and FGF23
Frontal lobe. There was a significant correlation between the left frontal lobe density and
FGF23 (Fig 2B left panel) in participants with CV risk factors such that participants with ele-
vated FGF23 had fewer fiber connections in their left frontal lobe (r = -0.42, p = 0.05). We fur-
ther calculated correlation on 17 participants with creatinine scores (partial correlation
Table 1. Multiple linear regression models for modularity in participants with cardiovascular risk factors.
Outcome Model Variables
FGF23 Gender
Female vs male
Race
White vs black
CCI
LH frontal
Adj.R2 = 0.38 B (SE) 0.03 (0.01) -0.06 (0.03) -0.01 (0.03) 0.02 (0.01)
F = 4.20 β 0.52 -0.43 -0.10 0.31
RH frontal
Adj.R2 = 0.21 B (SE) 0.02 (0.02) -0.05 (0.04) 0.01 (0.04) 0.04 (0.02)
F = 2.40 β 0.17 -0.26 0.05 0.55
LH parietal
Adj.R2 = 0.12 B (SE) -0.02 (0.02) -0.01 (0.04) 0.09 (0.04) -0.01 (0.02)
F = 1.72 β -0.25 -0.07 0.57 -0.10
RH parietal
Adj.R2 = 0.03 B (SE) -0.01 (0.02) -0.05 (0.03) 0.03 (0.03) 0.01 (0.01)
F = 1.19 β -0.18 -0.36 0.23 0.14
LH temporal
Adj.R2 = -0.12 B (SE) -0.00 (0.01) -0.02 (0.02) -0.01 (0.02) 0.01 (0.01)
F = 0.44 β -0.07 -0.22 -0.10 0.30
RH temporal
Adj.R2 = 0.12 B (SE) 0.01 (0.01) -0.05 (0.03) 0.01 (0.03) 0.01 (0.03)
F = 1.70 β 0.11 -0.44 0.04 0.34
LH occipital
Adj.R2 = 0.22 B (SE) -0.01 (0.01) -0.02 (0.03) 0.07 (0.03) 0.01 (0.01)
F = 2.49 β -0.21 -0.18 0.55 0.10
RH occipital
Adj.R2 = -0.10 B (SE) 0.01 (0.01) -0.01 (0.03) 0.02 (0.03) 0.01 (0.01)
F = 0.51 β 0.12 -0.07 0.20 0.12
p < .05.
p < .01.
B = parameter estimate, SE = standard error, β = standardized estimate, CCI = Charlson Comorbidity Index, LH = left hemisphere, RH = right hemisphere
https://doi.org/10.1371/journal.pone.0203460.t001
FGF23 and the brain
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controlling for creatinine: r = -0.40, p = 0.07). An association was not observed in the left
frontal hemisphere of participants without CV risk factors (r = -0.04, p = 0.58, Fig 2B right
panel).
Discussion
In this study, we aimed to determine the relationship between CV risk factors, FGF23 levels,
integrity of axonal fibers, and white matter network topological organization. We employed
high resolution structural connectomes constructed from diffusion imaging to measure indi-
vidual network integration and segregation via modularity. We hypothesized that elevated
FGF23 levels would be associated with the reduction of white matter fiber connections, and
loss of organization (fragmentation) of white matter networks. We demonstrated a relation-
ship between FGF23 and left frontal lobe network integrity, and showed that in participants
with CV risk factors, FGF23 levels accounted for up to 29% of left hemisphere frontal lobe net-
work integrity, meaning that participants with elevated FGF23 levels and CV risk factor bur-
den had higher modularity scores, indicating a disruption of the brain network organization.
Table 2. Multiple linear regression models for modularity in healthy controls.
Outcome Model Variables
FGF23 Gender
Female vs male
Race
White vs black
CCI
LH frontal
Adj.R2 = 0.38 B (SE) 0.03 (0.01) -0.06 (0.03) -0.01 (0.03) 0.02 (0.01)
F = 4.20 β 0.52 -0.43 -0.10 0.31
RH frontal
Adj.R2 = 0.32 B (SE) 0.02 (0.01) 0.08 (0.04) 0.10 (0.03) 0.02 (0.01)
F = 4.12 β 0.17 0.29 0.62 0.20
LH parietal
Adj.R2 = 0.23 B (SE) -0.01 (0.02) 0.10 (0.06) 0.11 (0.04) 0.03 (0.02)
F = 2.97 β -0.04 0.31 0.52 0.27
RH parietal
Adj.R2 = 0.15 B (SE) 0.01 (0.02) 0.12 (0.07) 0.11 (0.04) 0.03 (0.02)
F = 2.21 β 0.06 0.32 0.47 0.22
LH temporal
Adj.R2 = 0.49 B (SE) 0.02 (0.01) 0.02 (0.03) 0.08 (0.02) 0.04 (0.01)
F = 7.48 β 0.20 0.08 0.57 0.50
RH temporal
Adj.R2 = 0.06 B (SE) 0.01 (0.01) 0.01 (0.04) 0.05 (0.02) 0.01 (0.01)
F = 1.45 β 0.18 0.07 0.40 0.18
LH occipital
Adj.R2 = 0.31 B (SE) -0.01 (0.01) 0.06 (0.03) 0.03 (0.02) 0.03 (0.01)
F = 4.08 β -0.20 0.37 0.24 0.49
RH occipital
Adj.R2 = 0.23 B (SE) 0.01 (0.01) -0.02 (0.03) 0.05 (0.02) 0.02 (0.01)
F = 3.07 β 0.16 -0.12 0.47 0.24
p < .05.
p < .01.
B = parameter estimate, SE = standard error, β = standardized estimate, CCI = Charlson Comorbidity Index, LH = left hemisphere, RH = right hemisphere
https://doi.org/10.1371/journal.pone.0203460.t002
FGF23 and the brain
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Sex, race, and CCI explained a further 9% of left frontal lobe integrity. FGF23 was not signifi-
cantly associated with brain integrity in participants without CV risk factors, although race,
sex and CCI were significantly associated with brain integrity in this group.
Our results complement and help explain previous findings suggesting that elevated FGF23
is associated with stroke and small vessel disease (SVD) independent of CKD. SVD is routinely
observed in normal ageing or individuals with CV risk factors and discovered incidentally on
routine MRIs by white matter hyperintensities (WMH). The Northern Manhattan study
(NOMAS) prospectively assessed 2,525 individuals from a racially diverse population and con-
cluded that elevated FGF23 conferred an overall risk of stroke and intracerebral hemorrhage
independent of CKD[8]. In a subset of the same cohort, (n = 1170), they also showed that ele-
vated FGF23 was associated with WMH, demonstrating a link between FGF23 and SVD in the
Fig 2. A) Left panel–correlation between left hemisphere frontal lobe modularity and FGF23 in the CV risk factor group. Right panel–correlation between left
hemisphere frontal lobe modularity and FGF23 in the control group. B) Left panel—correlation between left hemisphere frontal lobe density and FGF23 in the CV risk
factor group. Right panel–correlation between left hemisphere frontal lobe density and FGF23 in the control group.
https://doi.org/10.1371/journal.pone.0203460.g002
FGF23 and the brain
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absence of CKD[17]. The Professional Follow-up Study (n = 1261) further showed elevated
FGF23 in individuals with established CV risk factors and higher dietary phosphate intake.
Our study builds on this previous literature by employing an approach that quantifies net-
work integrity; and may detect subclinical structural compromise; to assess the tripartite asso-
ciation between CV risk factors, FGF23, and white matter integrity. We employed a fine-
grained atlas to improve our statistical power, and for a more detailed connectome; we did not
assess the effect of using functionally relevant atlases, although whole brain tractography did
yield functionally relevant modules (Fig 1 panel C)
We observed reduced network density, and a disorganization of the left frontal hemisphere
network topology related to elevated FGF23, exclusively in participants with CV risk factors.
Importantly, we showed that FGF23 is an independently associated with brain integrity in par-
ticipants diagnosed with CV risk factors. Since FGF23 is a modifiable risk factor, understand-
ing this association may be an important step in reducing stroke incidences, stroke severity,
and improving outcome after stroke. Brain integrity of normal ageing individuals was still
explained by age and comorbidity (captured by CCI), sex, and race, although with the current
limited sample size, we cannot conclusively draw any conclusions on the significance of sex
and race.
The frontal hemisphere supports several cognitive processes including problem solving,
memory, language, judgement, social behavior and impulse control. Therefore, the association
between FGF23 and compromised structural integrity of the frontal lobe further provides an
interesting first step towards understanding the impact of FGF23 on cognition. The fiber loss
localized to the left hemisphere, indicating that the relationship between FGF23 and network
fragmentation is restricted to the dominant hemisphere (all participants except 1in the CV
group were right handed). This observation may indicate a more pronounced susceptibility to
injury in the dominant hemisphere.
The limitations of this study are: 1) we did not assess the association between white matter
network integrity and behavioral function since a comprehensive assessment of neuropsycho-
logical performance was not available in this cohort. We believe that this would be an impor-
tant future direction, specifically testing the impact of FGF23 on cognitive control and
executive function, which are frontal lobe dependent measures. 2) This is an initial pilot study
with a relatively small sample size. Furthermore, the multiple linear regression models were
not controlled for multiple comparisons, even though we did account for multiple confound-
ers. 3) BMI and smoking history are important CV risk factors that were not included in the
analyses. 4) Our cohort is made up of 80% women and is therefore not a not representative
sample of the general population.
Based on the findings of this study, we believe that there are important possible future
directions to continue to elucidate the impact of FGF23 on brain health, namely 1) the assess-
ment of the cognitive impact of FGF23, and whether FGF23 leads to subclinical yet quantifi-
able cognitive compromise, particularly in frontal lobe functions; 2) the evaluation of the
continuum between the impact of FGF23 on brain health across the spectrum ranging from
normal kidney function to end-state CKD; 3) the assessment of the synergistic effects of
FGF23 with other CV, electrolyte and kidney function biomarkers; and 4) the concurrent eval-
uation of connectome with other measures of brain integrity, including T2 weighted microan-
giopathic lesion burden.
In summary, we demonstrated the association between elevated serum FGF23, fiber loss
and network disintegration in the frontal region of the left hemisphere. This relationship
between FGF23 and brain integrity was noted in individuals without CKD, but with CV risk
factors. We postulate a synergistic interaction of CV risk factors and FGF23 as a potentially
novel determinant of brain health.
FGF23 and the brain
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